ACCEPTED MANUSCRIPT


Supplementary Table 1. Subsequent therapy with docetaxel among elderly and younger subgroups (intent-to-treat population)

	Elderly (≥7	5 years)	Younger (<75 years)			
	Abiraterone-prednisone	Prednisone alone	Abiraterone-prednisone	Prednisone alone		
	(n = 185)	(<i>n</i> = 165)	(n = 361)	(n = 377)		
Subsequent therapy with	59 (31.9)	68 (41.2)	180 (49.9)	236 (62.6)		
docetaxel, n (%)		Ç				
No subsequent therapy	126 (68.1)	97 (58.8)	181 (50.1)	141 (37.4)		
with docetaxel, n (%)						

Supplementary Table 2. Adverse events reported during treatment, by 3 age categories (safety population)

	≥75 years				65–74 years			<65 years				
	Abiraterone-		Prednisone alone		Abiraterone-	Prednisone alone		Abiraterone-		Prednisone alone		
	predn	isone	(n=1	164)	predni	isone	(n=2	222)	predn	isone	(n=1	154)
	(n=1	182)			(n=2	25)			(n=1	135)		
-	Grades	Grades	Grades	Grades	Grades	Grades	Grades	Grades	Grades	Grades	Grades	Grades
	1-4	3/4	1-4	3/4	1-4	3/4	1-4	3/4	1-4	3/4	1-4	3/4
Subjects with TEAE, n (%)	182	104	163	92	223	109	214	88	133	54	147	55
	(100.0)	(57.1)	(99.4)	(56.1)	(99.1)	(48.4)	(96.4)	(39.6)	(98.5)	(40.0)	(95.5)	(35.7)
TEAE leading to death, n (%)	14 (7.7)		9 (5.5)		5 (2.2)		5 (2.3)		2 (1.5)		2 (1.3)	

TEAE = treatment-emergent adverse event.



(n = 1533)

Screen failures (n = 445)

ITT population (N = 1088)

(All subjects randomized) 1:1 ratio (Abiraterone-prednisone: Prednisone alone)

Abiraterone-prednisone (n = 546) Prednisone alone (n = 542)

Did not receive study medication

Abiraterone-prednisone (n = 4) Prednisone alone (n = 2)

Safety population (N = 1082)

(All subjects who receive any study medication)

Abiraterone-prednisone (n = 542) Prednisone alone (n = 540)